Amarin Corp Plc (AMRN)

[everyonesguess]

Fortunately, the RRR and CV Death from RI are 25% and 20% (with p < 0.001), respectively. MO can never pull those effect back to p > 0.0426. I don't think MO will be an issue for FDA approval. MO has prolonging clinical-history in literatures. FDA has known that. The most is doing a P IV study (as a record for reference) to compare MO + statin (used in RI) against statin (used in RI) in LDLC.

In my view, MO was not real issue. It is just a fake issue for hitting AMRN's PPS to expire related options (with huge open interest).

For next week, the lingering margin calls may still impact the PPS for a day or so. Then the PPS should be heading to where it should be ($30 prior to BO -- BP want V badly).